Tumor is a new organism≥∑∞ formed by abnormal prolifera¥≤★tion of cells due to the loss of control ≥βπ​of local cells' growth at the gen™'≥e level under the action of various tumorigeni¥←↑c factors. According to the biologica¶✘↑$l characteristics of tumors and their different &§∏±degrees of harm to the body, they can be ±δdivided into benign aδ‍λ"nd malignant tumors.∏← In China, malignant tumor is one of the mai≈ >•n causes of death of patients, and its incidenceβγ•↑ and mortality are rising, bσ≥αecoming a very serious public health pro<λπ↑blem.

Tumor therapy has always been a hot ar€φ≥ea of drug research and development, in whi$<ch biological drugs play an importa≈λnt role. The biological÷π∏ targeted therapy of tumor is to design t±∞£he corresponding therapeutic drug¥€s (antibodies, CAR-T, etc.) at thσ♦‍e cellular and molecular level, aiming at₽∏→ the identified target♠•s, so as to play the role of ✘λinhibiting and killin∑‍∞♥g tumor.

Compared with monotherapy ' ✘or traditional combination therapy, t÷∞he dual target properties of bispecific an≤δtibodies have key advantages in improving ↕πφthe antitumor efficacy: (1) simultaneouslyδ₩® blocking two different targ↓ ±ets or mediators that play a major role in&φ the pathogenesis of the disease; (2) Induc≥>€tion of cellular signaling pat≠<≠→hways (e.g., proliferation or inflamm£<atory pathways); (3) Retarge✔≠βting to regulate ADCC; (4)•π​λ Avoiding the progression of drug resistan£δce and improving the anti proliferative δ₹γeffect; (5) The patient's own cy€£totoxic T cells are temporarily c​₹ombined with targeted cancer≥ ®↑ cells, thereby activating cytotoxic T cells to ✔α‌←cause tumor lysis.